Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-Muscle Invasive Bladder Neoplasms 1Myelodysplastic Syndromes 1Metabolism, Inborn Errors 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Immunologic Deficiency Syndromes 1Hemoglobinopathies 1Graft vs Host Disease 1Congenital Bone Marrow Failure Syndromes 1Carcinoma in Situ 1Bone Marrow Failure Disorders 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Magnetic Resonance Spectroscopy 54enzalutamide 47apalutamide 37Specimen Handling 37Androgen Antagonists 34Abiraterone Acetate 32Prednisone 29darolutamide 28Radiosurgery 27Pluvicto 23Docetaxel 23abiraterone 22Radiotherapy 21Leuprolide 19Biopsy 16relugolix 14acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 14Surveys and Questionnaires 13gallium 68 PSMA-11 12Triptorelin Pamoate 12Gonadotropin-Releasing Hormone 12Radiation 11Nivolumab 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11cabazitaxel 10bicalutamide 10X-Rays 10Standard of Care 10Goserelin 9Carboplatin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Clinical Trials, Phase I as Topic × 90 days × Clear all
NCT01171898 2026-05-11

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Aragon Pharmaceuticals, Inc.

Phase 1/2 Completed
127 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡